Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115479
Status:
COMPLETED
Last Update Posted:
2006-05-04
First Post:
2005-06-22
Brief Title:
KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients
Sponsor:
KU Leuven
Organization:
KU Leuven
Study Overview
Official Title:
KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients
Status:
COMPLETED
Status Verified Date:
2005-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In a previous study we showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical intensive care patients Whether this intervention also improves prognosis of medical intensive care patients remains unknown The current prospective randomized controlled study will assess the impact of intensive insulin therapy on the outcome of patients in a medical intensive care unit On admission patients will be randomly assigned to either strict normalization of blood glucose 80-110 mgdl with intensive insulin therapy or the conventional approach in which insulin infusion is initiated only when blood glucose exceeds 215 mgdl to maintain blood glucose levels between 180 and 200 mgdl
Detailed Description:
In a previous study we showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical intensive care patients Whether this intervention also improves prognosis of medical intensive care patients remains unknown The current prospective randomized controlled study will assess the impact of intensive insulin therapy on the outcome of patients in a medical intensive care unit On admission patients will be randomly assigned to either strict normalization of blood glucose 80-110 mgdl with intensive insulin therapy or the conventional approach in which insulin infusion is initiated only when blood glucose exceeds 215 mgdl to maintain blood glucose levels between 180 and 200 mgdl
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| KULeuven OT0356 | None | None | None |
| FWO grant number G027803 | None | None | None |